SAR 101099Alternative Names: SAR101099
Latest Information Update: 29 Feb 2012
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Mechanism of Action Urotensin II antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetic nephropathies
Most Recent Events
- 08 Feb 2012 Discontinued - Phase-I for Diabetic nephropathies in Europe (unspecified route)